| Sex ratio (female/male) | 1.35 (23/17) |
| Age, y* | 53.5 ± 23.1 |
| Disease duration, mo* | 33 ± 56 |
| Platelet count at diagnosis, ×109/L* | 19 ± 18.8 |
| Number of treatments* | 3.7 ± 2.5 |
| Treatments | |
| Number of patients (%) | |
| Steroids | 37 (92.5%) |
| Rituximab | 19 (47.5%) |
| IVIg | 19 (47.5%) |
| Dapsone | 19 (47.5%) |
| Splenectomy | 14 (35%) |
| Danazol | 3 (7.5%) |
| Other | 7 (17.5%) |
| Sex ratio (female/male) | 1.35 (23/17) |
| Age, y* | 53.5 ± 23.1 |
| Disease duration, mo* | 33 ± 56 |
| Platelet count at diagnosis, ×109/L* | 19 ± 18.8 |
| Number of treatments* | 3.7 ± 2.5 |
| Treatments | |
| Number of patients (%) | |
| Steroids | 37 (92.5%) |
| Rituximab | 19 (47.5%) |
| IVIg | 19 (47.5%) |
| Dapsone | 19 (47.5%) |
| Splenectomy | 14 (35%) |
| Danazol | 3 (7.5%) |
| Other | 7 (17.5%) |
Mean ± SD.